Imcyse – Trademark Portfolio

Entity Type: 99

Imcyse holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 2 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 3 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include IMOTOPE. The owner is based in B-4000 Liège.

Avenue de l'hôpital 1

Tour GIGA (B34)

B-4000 Liège , BE

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

IMOTOPE
IMOTOPE
Registered 2023

Trademark Classifications

Imcyse's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

42
Computer & Scientific (2 filings)

Scientific and technological services; industrial analysis and research services

44
Medical Services (2 filings)

Medical services; veterinary services; hygienic and beauty care for human beings or animals

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Imcyse have?

Imcyse has 2 U.S. trademarks filed with the USPTO. Of these, 1 registered.

What trademark classes does Imcyse file in?

Imcyse files trademarks across 3 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.

What are Imcyse's most well-known trademarks?

Imcyse's registered trademark portfolio includes well-known marks such as IMOTOPE. These are among 1 currently registered trademark in the portfolio.

What is Imcyse's trademark registration success rate?

Imcyse has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.